» Articles » PMID: 24814851

Correlation of Clinical and Molecular Features in Spinal Bulbar Muscular Atrophy

Overview
Journal Neurology
Specialty Neurology
Date 2014 May 13
PMID 24814851
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To characterize the clinical and genetic features of spinal bulbar muscular atrophy (SBMA), a rare neurodegenerative disorder caused by the expansion of a CAG repeat in the first exon of the androgen receptor gene, in the United Kingdom.

Methods: We created a national register for SBMA in the United Kingdom and recruited 61 patients between 2005 and 2013. In our cross-sectional study, we assessed, by direct questioning, impairment of activities of daily living (ADL) milestones, functional rating, and subjective disease impact, and performed correlations with both CAG repeat size and degree of somatic mosaicism. Ten patients were deceased, 46 patients participated in the study, and 5 declined.

Results: Subjects had an average age at onset of 43.4 years, and weakness onset most frequently occurred in the lower limbs (87%). Impaired mobility was the most frequently reported problem by patients, followed by bulbar dysfunction. Age distribution of the impairment of ADL milestones showed remarkable overlap with a Japanese study. We have identified a significant correlation between the number of CAG repeats and both age at onset and ADL milestones. Somatic mosaicism also showed a correlation with CAG expansion size and age at onset.

Conclusions: Clinical features in SBMA show a substantial overlap when comparing populations with different genetic backgrounds. This finding has major implications, because multicenter trials will be necessary to obtain sufficient power in future clinical trials. Clinical-genetic correlations are strong in SBMA and should inform any clinical research strategy in this condition.

Citing Articles

Therapeutic targeting of the polyglutamine androgen receptor in Spinal and Bulbar Muscular Atrophy.

Sangotra A, Lieberman A Expert Opin Ther Targets. 2025; 29(1-2):29-41.

PMID: 39915972 PMC: 11888889. DOI: 10.1080/14728222.2025.2464173.


One case of spinal bulbar muscular atrophy misdiagnosed as polymyositis: Case report.

Mu Y, Yao J, Li F Medicine (Baltimore). 2024; 103(39):e39169.

PMID: 39331876 PMC: 11441867. DOI: 10.1097/MD.0000000000039169.


Patient-Reported Impact of Symptoms in Spinal and Bulbar Muscular Atrophy.

Alqahtani A, Kokkinis A, Zizzi C, Dilek N, Fischbeck K, Heatwole C Neurol Clin Pract. 2024; 13(6):e200213.

PMID: 39140081 PMC: 11318780. DOI: 10.1212/CPJ.0000000000200213.


Incidence and prevalence of Spinal and bulbar muscular atrophy in South Korea: a nationwide population-based study.

Park J, Kang M, Park J J Neurol. 2023; 270(10):5017-5022.

PMID: 37389590 DOI: 10.1007/s00415-023-11842-8.


Unexpected frequency of the pathogenic AR CAG repeat expansion in the general population.

Zanovello M, Ibanez K, Brown A, Sivakumar P, Bombaci A, Santos L Brain. 2023; 146(7):2723-2729.

PMID: 36797998 PMC: 10316764. DOI: 10.1093/brain/awad050.


References
1.
Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, Leguern E . A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab. 2002; 87(8):3893-901. DOI: 10.1210/jcem.87.8.8780. View

2.
Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y . Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005; 128(Pt 3):659-70. DOI: 10.1093/brain/awh381. View

3.
La Spada A, Wilson E, Lubahn D, Harding A, Fischbeck K . Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991; 352(6330):77-9. DOI: 10.1038/352077a0. View

4.
Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. DOI: 10.1016/s0022-510x(99)00210-5. View

5.
Fernandez-Rhodes L, Kokkinis A, White M, Watts C, Auh S, Jeffries N . Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011; 10(2):140-7. PMC: 3056353. DOI: 10.1016/S1474-4422(10)70321-5. View